Insulet stock stands 13.26 percent above its 52-week low

Published on 10/20/2026 at 18:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal 2025 revenue reached USD 2.7 billion, with more than 600,000 customers. Insulet stock costs EUR 127.60 on October 20, 2026.

Price position and business scale

Insulet stock stood 13.26 percent above its 52-week low on October 20, 2026.
Fiscal 2025 revenue reached USD 2.7 billion, with more than 600,000 global customers.
Insulet stock costs EUR 127.60 at Lang & Schwarz on October 20, 2026 at 6:36 p.m. CEST.

Flatlay Insulet – Aktienzertifikat, ISIN-Karte US45784P1012, Pod-Gerät und Stethoskop auf Marmor — Insulet Aktien-Flatlay auf weißem Marmor mit Börsenzertifikat, ISIN-Karte US45784P1012, Insulin-Pod und Stethoskop, Illustration mit AI erstellt.

Insulet stock stood 13.26 percent above its 52-week low on October 20, 2026, with the Nasdaq quote at USD 143.16 and the low at USD 126.40. The company serves the diabetes market through its Omnipod platform. At Lang & Schwarz, the euro quotation was EUR 127.60 on October 20, 2026 at 6:36 p.m. CEST.

Revenue and customer scale

Insulet reported USD 2.7 billion in revenue for fiscal year 2025 and said more than 600,000 customers used its products worldwide. The company operates in 26 countries, while Omnipod remains the central product platform for wearable insulin delivery.

The revenue figure places the business well above the USD 801.70 million reported for the second quarter of fiscal year 2026, a period in which revenue increased 23.50 percent year over year, according to ScanX News. That comparison is historical context for the current quotation rather than a new earnings release.

52-week range sets the frame

The Nasdaq quote of USD 143.16 at 12:40 p.m. EDT on October 20, 2026 placed Insulet between its USD 126.40 52-week low and USD 354.88 high. The stock was therefore 59.67 percent below its 52-week high, a wider distance than its 13.26 percent position above the low. Market capitalization stood at USD 9.9 billion, and the price-to-earnings ratio was 26.79 at the same market-data timestamp.

Valuation and November 4 date

Insulet's next scheduled reporting date is November 4, 2026, before the U.S. market opens, with an earnings call at 8:00 a.m. Eastern Time. The date was announced by Insulet on October 1, 2026. The upcoming report will give investors a new test of customer growth and product adoption after the strong fiscal-year revenue base.

Comparison with peers

Insulet: up 0.84 percent on Nasdaq, price-to-earnings ratio 26.79, market capitalization USD 9.9 billion on October 20, 2026. DexCom (Nasdaq, USD): down 0.65 percent, price-to-earnings ratio 33.75, market capitalization USD 32.2 billion on October 20, 2026. Abbott Laboratories (NYSE, USD): down 0.93 percent, price-to-earnings ratio 33.05, market capitalization USD 178.4 billion on October 20, 2026.

Insulet stock after the Xetra session

The euro quotation stood at EUR 127.60 at Lang & Schwarz on October 20, 2026 at 6:36 p.m. CEST, while the Nasdaq quote was USD 143.16 at 12:40 p.m. EDT. The further course of trading is shown by the continuously updated real-time quote of Insulet stock.